cefaclor - Profile

What are the generic sources for cefaclor and what is the scope of patent protection?

Cefaclor is the generic ingredient in four branded drugs marketed by Lilly, Ceph Intl, Chartwell Rx, Dava Pharms Inc, Hikma, Ivax Sub Teva Pharms, Ranbaxy, Teva, Yung Shin Pharm, Facta Farma, Watson Labs Inc, Ranbaxy Labs Ltd, and World Gen, and is included in thirty-three NDAs. Additional information is available in the individual branded drug profile pages.

Summary for cefaclor

US Patents:	0
Tradenames:	4
Applicants:	13
NDAs:	33

US Patents and Regulatory Information for cefaclor

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lilly	CECLOR	cefaclor	CAPSULE;ORAL	050521-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Lilly	CECLOR	cefaclor	CAPSULE;ORAL	050521-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Ceph Intl	CEFACLOR	cefaclor	CAPSULE;ORAL	062205-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Ceph Intl	CEFACLOR	cefaclor	CAPSULE;ORAL	062205-002	Approved Prior to Jan 1, 1982		DISCN	No	No

CEFACLOR: Investment Scenario and Fundamentals Analysis

Last updated: April 25, 2026

What is cefaclor and how does it sit in the market?

Cefaclor is an oral second-generation cephalosporin (β-lactam) antibiotic used to treat bacterial infections where susceptibility supports cephalosporin therapy. From an investment perspective, cefaclor’s relevance tracks to three fundamentals: (1) residual demand for legacy oral antibiotics, (2) competitive intensity from newer cephalosporins and alternative antibiotic classes, and (3) patent and regulatory exclusivity status that determines how much innovator-margin premium remains.

Key implication: cefaclor is a mature, largely off-patent small-molecule antibiotic where value typically concentrates in generics manufacturing scale, supply stability, and low-cost compliance rather than in new clinical entrants with proprietary differentiation.

What does the patent and exclusivity landscape imply for pricing power?

Public patenting for early cephalosporin generations has largely run its course for cefaclor. In practice, that means:

• Brand-level pricing power is limited to the extent that authorized generics and multiple generics compete.
• New entrant barriers are primarily regulatory (ANDA chemistry and bioequivalence) and supply-chain execution, not clinical innovation or exclusivity.

In a mature antibiotic segment, the economic model usually shifts to:

• Volume-driven economics for low-margin generics
• Portfolio leverage across multiple cephalosporins for manufacturing optimization
• Contracting discipline with wholesalers and institutional formularies

What are the demand drivers and where does volume come from?

Cefaclor’s demand tends to follow:

• Infectious disease incidence (respiratory and skin/soft-tissue indications commonly drive use patterns for oral cephalosporins)
• Payer and formulary treatment pathways that favor guideline-supported antibiotic choices
• Generic substitution dynamics after patent expiry and during supply periods

For investment analysis, the practical demand question is not “is cefaclor used,” but:

• How consistently does it remain in formularies where clinicians still choose oral cephalosporins for susceptible infections?
• Can manufacturers maintain uninterrupted supply at competitive prices?

How does competition shape the earnings profile?

Second-generation oral cephalosporins compete against:

• Other cephalosporins with broader clinician preferences or different dosing convenience
• Non-cephalosporin antibiotic classes when resistance patterns and stewardship guidelines steer selection

This market structure typically produces:

• Price compression over time with new generic launches
• Short-term manufacturer premium only when supply disruptions create temporary scarcity
• Margin volatility tied to raw material costs, capacity utilization, and regulatory inspection outcomes

What does stewardship and resistance risk mean for investment exposure?

Antibiotics operate under tighter stewardship controls, which affects:

• Prescribing behavior and treatment duration
• Formularies and prior authorization rules in some payer systems
• Public health surveillance that can change recommended empiric options

For cefaclor specifically, investment risk is concentrated in:

• Reputational and policy risk around antibiotic use if utilization declines or restrictions increase
• Clinical switching risk to alternative oral agents when susceptibility patterns change

This is less about individual clinical trial outcomes and more about real-world guideline evolution.

How stable is manufacturing and regulatory execution risk?

For off-patent generics, the primary fundamentals are operational:

• Bioequivalence and manufacturing compliance under current good manufacturing practice (cGMP)
• Ability to scale with consistent quality across lots
• Regulatory inspection readiness and batch release timelines
• Supply continuity in API sourcing and finished-dose production

Investment interpretation:

• Firms with mature cephalosporin manufacturing footprints tend to exhibit more resilient gross margins because they can lower unit costs and reduce downtime risk.
• Firms with narrower product bases often face greater earnings volatility in mature antibiotic portfolios.

What product-level economics usually govern cefaclor generics?

Cefaclor economics in mature markets typically follow:

• Wholesale and pharmacy channel reimbursement compression
• Tender-based pricing for institutional supply
• Trade-down dynamics when competitors launch lower price points

The most actionable investor lens is to model:

• Net sales sensitivity to price declines typical of generic segments
• COGS sensitivity to β-lactam manufacturing chemistry inputs and solvent/API costs
• SG&A sensitivity to tender frequency and contracting cycles

Where are growth opportunities likely to exist?

Growth is usually limited for a mature antibiotic unless the company has an operational edge. Credible pathways include:

1. Formulation and packaging advantages in specific markets or pediatric dosing lines
2. Expanded supply agreements with large distributors or hospital groups
3. Geographic scaling where generic market share remains fragmented
4. Portfolio cross-selling into adjacent cephalosporins to smooth utilization

Without proprietary exclusivity, growth typically means market share capture and cost leadership, not margin preservation.

What are the strategic investment scenarios for a cefaclor-focused position?

Scenario A: “Share + supply reliability” thesis

Core bet: Cefaclor demand remains steady enough that a low-cost, high-compliance manufacturer can capture volume even as pricing compresses.

Fundamental checklist

• Stable manufacturing capacity and validated QC systems
• Low unit cost and predictable batch release performance
• Contracting capability in tenders and distributor agreements

Primary upside

• Market share gains during competitor shortages
• Sustained formulary presence for oral second-generation cephalosporins

Primary downside

• Rapid price compression as new generic competitors enter or expand
• Regulatory setbacks that interrupt supply

Scenario B: “Portfolio defensive income” thesis

Core bet: Cefaclor is used as part of a broader generics antibiotic platform where cross-supply stabilizes utilization and cash flow.

Fundamental checklist

• Diversified sterile and non-sterile product base
• Ability to shift production between cephalosporin SKUs
• Strong distribution relationships and predictable reimbursement channels

Primary upside

• Smoother earnings due to portfolio mix
• Better bargaining power in procurement and contracting

Primary downside

• Macro antibiotic utilization declines driven by stewardship
• Margin drift across the entire antibiotic generic category

Scenario C: “Mature market value play” thesis

Core bet: The asset is already priced as mature and value investors focus on operational execution and capital efficiency rather than growth narratives.

Fundamental checklist

• Clear cost-down roadmap and CAPEX discipline
• Tight working capital management due to wholesaler payment cycles
• Proven scale in cephalosporin API and finished dose manufacturing

Primary upside

• Re-rating via margin stabilization
• Cash return via buybacks/dividends if leverage falls

Primary downside

• Chronic underperformance if pricing falls faster than cost improvements

What should investors monitor each quarter?

For cefaclor exposure, the key KPIs are operational rather than clinical:

• Net sales growth vs. price/mix
• Gross margin trend and drivers tied to COGS and manufacturing yield
• Batch release timelines and rejection rates
• Regulatory status: warning letters, consent decrees, or inspection outcomes
• Formulary/tender retention via distributor and institutional purchasing signals

A mature cephalosporin position is a test of execution. Investors should treat earnings quality as the metric that matters most.

How does cefaclor compare with typical small-molecule antibiotic incumbents?

Cefaclor competes in a segment where new entrants rarely deliver durable differentiation because:

• Most economic value becomes generic pricing and volume capture after exclusivity.
• Differentiation shifts toward:
  • manufacturing scale
  • cost position
  • supply reliability
  • portfolio breadth

Comparison framework (generic antibiotic segment)	Dimension	Typical cefaclor outcome	Investor implication
Exclusivity	Limited, largely resolved	Margin ceiling at generic levels
Competition	High, multi-brand generics	Price compression risk
Growth	Market share and geography dependent	Value shifts to execution
Earnings drivers	Manufacturing yield and COGS	Operational KPI focus
Policy risk	Stewardship can reduce use	Monitor utilization trends

Investment conclusion: what is the most likely fundamental profile?

Cefaclor fundamentals point to a mature generic antibiotic cash-flow profile. In such settings, the most investable differentiators are:

• Manufacturing excellence (yield, compliance, uptime)
• Cost leadership (API sourcing and unit economics)
• Commercial execution (tender wins and distributor access)
• Portfolio construction that reduces dependency on a single SKU

For R&D investors, cefaclor is not a proprietary innovation story. For operational investors, it is a platform economics story.

---

Key Takeaways

• Cefaclor is a mature, oral second-generation cephalosporin where economics depend on generic competition, pricing compression, and manufacturing execution.
• Patent/exclusivity impact is largely resolved, limiting brand-level pricing power and shifting value toward scale and cost.
• Demand is stewardship- and guideline-sensitive, so utilization trends can move faster than supply capacity.
• The investable edge is operational: cGMP reliability, QC yield, batch release discipline, and supply continuity.
• Best-aligned positions are share capture and portfolio defensive income theses, not premium innovation or exclusivity-driven upside.

FAQs

1. Is cefaclor likely to be a growth catalyst for an innovator?
   No. The fundamentals align with mature generics economics rather than exclusivity-driven growth.

2. What drives cefaclor earnings most in a generic-focused company?
   COGS, manufacturing yield, batch release performance, and tender/distributor contracting outcomes.

3. What is the main competitive threat to cefaclor products?
   Continued entry or expansion by low-cost generic manufacturers that accelerate price compression.

4. How does antibiotic stewardship affect cefaclor?
   It can reduce or redirect prescribing, changing utilization and potentially pressuring volumes.

5. What risk matters most for supply reliability?
   Regulatory and manufacturing interruptions that delay releases or reduce acceptable lot availability.

---

References

[1] U.S. National Library of Medicine. “Cefaclor.” PubChem Compound Summary. https://pubchem.ncbi.nlm.nih.gov/ (accessed 2026-04-25).
[2] FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-04-25).
[3] World Health Organization. “WHO Model List of Essential Medicines.” https://www.who.int/ (accessed 2026-04-25).